An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment
Phase of Trial: Phase IV
Latest Information Update: 17 Jul 2019
At a glance
- Drugs Pasireotide (Primary) ; Cabergoline
- Indications Carcinoid tumour; Meningioma; Neuroendocrine tumours; Pituitary cancer; Prostate cancer; Uveal melanoma
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 07 Jul 2019 Pasireotide may be given either alone or in combination with Cabergoline (another treatment for Cushing's Disease and Acromegaly ), number of arm chaned from 1 to 2 and number of patients changed form 400 to 500.
- 07 Jul 2019 Planned number of patients changed from 400 to 500.
- 07 Jul 2019 Planned End Date changed from 12 Jun 2023 to 9 Jun 2023.